Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398212 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896049 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486287 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486214 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL118209 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL119497 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896048 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL6038102 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1564185 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398684 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036916-A | Ruitalu Process for producing peptide | 哈尔滨吉象隆生物技术有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122011107-A | Polypeptide, preparation method thereof and application thereof in delaying muscle attenuation | 内蒙古蒙牛乳业（集团）股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122011162-A | Chemical synthesis method of N-terminal domain of TIMP2 protein | 华南理工大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| CN-121574187-A | Application of donkey-source bioactive peptide and derivative thereof in cosmetics | 上海湃肽生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-121574188-A | Application of donkey-source bioactive peptide and its derivative in cosmetics | 上海湃肽生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250382345-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | LILLY CO ELI (US) | 2025-12-18 | — | — | US | claimed |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | SHANGHAI UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| US-20250282826-A1 | PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE | INNER MONGOLIA UNIVERSITY (CN) | 2025-09-11 | — | — | US | claimed |
| CN-112142825-B | Method for synthesizing carbetocin in fragment mode | 山东辰龙药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-109627286-B | Novel broad-spectrum antibacterial peptide SAMP1-A4 and preparation method thereof | 河南工业大学 | 2022-03-11 | — | — | CN | claimed |
| CN-111777669-B | Anti-tumor active peptide, synthesis method and application | 安徽工程大学 | 2022-03-08 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-114106050-A | Tight chiral environment biphenyl-phenanthrene framework chiral phosphoric acid and preparation method and application thereof | 华东理工大学 | 2022-03-01 | — | — | CN | claimed |
| CN-114085269-A | All-solid-phase synthesis method of Hoshinoamide A | 滁州学院 | 2022-02-25 | — | — | CN | claimed |
| CN-111777668-B | Marine cyclopeptide Samoamide A-based modified polypeptide, synthetic method and application | 安徽工程大学 | 2022-02-25 | — | — | CN | claimed |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | Indian Institute of Technology Indore (IN) | 2022-02-24 | — | — | US | claimed |
| CN-114057862-A | Synthetic method of GLP-1(1-37) polypeptide | 安徽省国平药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | CASP3 3659/4885MDM4 4227/4885TP53 4727/4885 |
| US-20250282826-A1 | PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE | VIP, PTMA, MLEC | CASP3 1519/4885MDM4 4560/4885TP53 2026/4885 |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | STING1, CGAS, VIP | CASP3 893/4885MDM4 1661/4885TP53 1709/4885 |
| US-20250382345-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | GLP1R, GIPR, GPR119 | CASP3 4305/4885MDM4 4854/4885TP53 4526/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | CASP3 1404/4885MDM4 3864/4885TP53 4243/4885 |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | TEK, VIP, SCTR | CASP3 1365/4885MDM4 4645/4885TP53 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.